[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D'Cruz AK, Parikh PM: In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer; 2007 Oct-Dec;44(4):142-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy.
  • Currently, it is difficult to predict whether a tumor will respond to chemotherapy and which drug(s) will achieve the maximum clinical response.
  • AIMS: To study in vitro chemosensitivity profile of oral cancers and to correlate the in vitro chemosensitivity of oral cancer to clinical response to chemotherapy.
  • METHODS AND MATERIAL: We prospectively studied the chemosensitivity profile of 57 untreated, advanced, unresectable oral cancers to cisplatin, methotrexate, 5-fluorouracil and their combinations by using histoculture drug response assay (HDRA) and correlated them to the clinical response to chemotherapy.
  • Of these 52 evaluable patients, 47 had primary gingivo-buccal cancers and five had tongue / floor of mouth cancers.
  • Of these, 31 patients with good performance status received two cycles of chemotherapy using one or more of these test drugs.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Biological Assay. Cisplatin / pharmacology. Cisplatin / therapeutic use. Female. Fluorouracil / pharmacology. Fluorouracil / therapeutic use. Humans. In Vitro Techniques. Male. Methotrexate / pharmacology. Methotrexate / therapeutic use. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322356.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • The mRNA levels have been measured in tumor cells microdissected from paraffin-embedded specimens (Danenberg Tumor Profile method: DTP method).
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


3. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM: Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):534-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor xenografts in athymic nude mice were used to assess the in vivo activity of panitumumab alone and combined with radiation.
  • In vivo, the combination therapy of panitumumab and radiation was superior to panitumumab or radiation alone in the H226 xenografts (p = 0.01) and showed a similar trend in the SCC-1483 xenografts (p = 0.08).
  • CONCLUSION: These studies have identified a favorable interaction in the combination of radiation and panitumumab in upper aerodigestive tract tumor models, both in vitro and in vivo.
  • These data suggest that clinical investigations examining the combination of radiation and panitumumab in the treatment of epithelial tumors warrant additional pursuit.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2005 Feb;74(2):109-15 [15734198.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31182-9 [16000298.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):157-61 [16024112.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):285-7 [16512986.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Cell Signal. 2006 Oct;18(10):1537-48 [16713182.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2233-44 [12134064.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4300-6 [12154033.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Int J Radiat Biol. 2003 Jul;79(7):581-5 [14530167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90 [14967460.001]
  • [Cites] Radiat Res. 1993 Oct;136(1):65-70 [8210340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):813-9 [8040028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]
  • [Cites] Radiat Res. 1996 Jan;145(1):81-5 [8532841.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]
  • [Cites] Radiat Oncol Investig. 1997;5(4):180-6 [9327497.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):781-7 [17096332.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1552-61 [17332301.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1134-43 [17921999.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]
  • [Cites] Radiother Oncol. 1999 Aug;52(2):137-48 [10577699.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Dec;14(6):451-63 [10850332.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4343-50 [11106252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):474-7 [11567823.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1236-43 [10096554.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3328-35 [15833866.001]
  • (PMID = 18793955.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / R01 CA113448-02; United States / NCI NIH HHS / CA / CA113448-04; United States / NCI NIH HHS / CA / R01 CA113448; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / CA113448-01A1; United States / NCI NIH HHS / CA / R01 CA113448-03; United States / NCI NIH HHS / CA / CA009614-12; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / R01 CA113448-05; United States / NCI NIH HHS / CA / CA009614-11; United States / NCI NIH HHS / CA / R01 CA 113448-01; United States / NCI NIH HHS / CA / T32 CA009614-13; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / R01 CA113448-04; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / R01 CA113448-01A1; United States / NCI NIH HHS / CA / CA113448-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Proliferating Cell Nuclear Antigen; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / panitumumab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS220555; NLM/ PMC2927815
  •  go-up   go-down


Advertisement
4. Epperly MW, Franicola D, Zhang X, Nie S, Greenberger JS: Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line. In Vivo; 2006 Nov-Dec;20(6B):791-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy of tumors of the head and neck region is compromised by dose limiting toxicity of normal tissues including the oral cavity and oropharyngeal mucosa.
  • MnSOD-Plasmid Liposome (MnSOD-PL) intraoral gene therapy has been demonstrated to decrease normal tissue toxicity and also improve survival in mice with orthotopic SCC-VII squamous cell tumors on the floor of the mouth.
  • Furthermore, intravenous administration of MnSOD-PL in mice with orthotopic tumors, or addition of MnSOD-PL to tumor cell lines in vitro produces a radiosensitizing effect attributable to differences in antioxidant pool responses of tumor cells compared to normal tissues following irradiation.
  • To determine whether EGF receptor (EGFR) antagonists Iressa, or Cetuximab provided further improvement of radiation killing of squamous cell tumors, MnSOD-PL transfected or control SCCVII tumor cells were irradiated in vitro, and then the effect of EGFR receptor antagonists was tested.
  • Cells transfected with MnSOD-PL were relatively radiosensitive D0 = 1.244 +/- 0.126 Gy compared to control D0 = 3.246 +/- 0.087 (p < 0.0001).
  • Clonogenic radiation survival curves of SCCVII cells demonstrated radiosensitization by Iressa D0 = 2.770 +/- 0.134 Gy (p = 0.0264), but no significant radiosensitizing effect of Cetuximab D0 = 3.193 +/- 0.309 (p = 0.7338).
  • The results suggest some synergy of the effectiveness of the EGFR antagonist Iressa on increasing the radiation killing of SCC-VII cells that supplements MnSOD-PL tumor radiosensitization.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / radiation effects. Cetuximab. Dose-Response Relationship, Radiation. Liposomes. Mice. Transfection. Transgenes / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] In Vivo. 2007 Nov-Dec;21(6):1172
  • (PMID = 17203769.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Quinazolines; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  •  go-up   go-down


5. Shikani AH, Domb AJ: Polymer chemotherapy for head and neck cancer. Laryngoscope; 2000 Jun;110(6):907-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymer chemotherapy for head and neck cancer.
  • OBJECTIVES: To study a new method of delivery of chemotherapy for the treatment of squamous cell carcinomas (SCCs) of the head and neck, to evaluate the pharmacokinetics of four anticancer agents (cisplatin, fluorouracil [5-FU], methotrexate [MTX], and paclitaxel) loaded into the biodegradable polymer, polyanhydride polymer poly(FAD:SA), and to evaluate the effectiveness and toxicity of the drug-polymer combination against human SCCs, both in vitro and in vivo.
  • STUDY DESIGN: Poly(FAD:SA) was loaded with different chemotherapeutic drugs and its in vitro and in vivo drug release and tissue penetration characteristics were studied.
  • The biocompatibility and toxicity of the polymer-drug combination were determined.
  • The effectiveness of the drug-polymer was evaluated against three different human SCCs (larynx O11, pharynx FADU, and floor of mouth UM- SCC1) cultured in vitro and in nude mice carrying human SCC xenografts.
  • METHODS: The in vitro drug release pharmacokinetics of the drugs were performed using atomic absorption spectrometry for cisplatin and high-pressure liquid chromatography for the 5-FU, MTX, and paclitaxel studies.
  • In vitro tumor cytotoxicity was assessed by growth assay.
  • RESULTS: All four chemotherapy drugs demonstrated a continuous release that followed first-order kinetics from the polymer.
  • Tumor cytotoxicity revealed that the polymer was very effective against the human SCCs O11, FADU, and UM- SCC1 in vitro.
  • The tumor animal model was the nude mouse carrying human floor of mouth SCC xenografts.
  • Different amounts of cisplatin were incorporated into the polymers (5% and 7% drug/polymer at a weight/weight [wt/wt] load).
  • Thirty-five days after implantation of the polymer in nude mice, the mean treated tumor size was 65.5% of controls in the 5% group and 31.8% in the 7% group.
  • Seventy days after implantation the mean treated tumor size was 41.4% of controls in the 5% group and 38.1% in the 7% group, indicating a statistically significant delay of tumor growth compared with controls or with intraperitoneally injected cisplatin.
  • The blank polymer was well tolerated by the mouse and had no effect on tumor growth.
  • CONCLUSIONS: The study results indicate that polymer chemotherapy is effective against a variety of SCCs of the head and neck, both in vitro and in vivo, and may become a useful therapeutic option for head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Polymers
  • [MeSH-minor] Animals. Biodegradation, Environmental. Chromatography, High Pressure Liquid / methods. Cisplatin / administration & dosage. Cisplatin / pharmacokinetics. Disease Models, Animal. Drug Carriers. Humans. Methotrexate / administration & dosage. Methotrexate / pharmacokinetics. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10852503.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Polymers; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G: Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer; 2008 Jul 8;99(1):93-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent preclinical and clinical studies suggest beneficial effects from combining anti-angiogenic drugs with RT.
  • To investigate the effect of combining these approaches, we evaluated in vivo the anti-tumour efficacy of the anti-angiogenic compound bevacizumab, a highly specific monoclonal antibody directed against the vascular endothelial growth factor (VEGF), erlotinib, an EGFR tyrosine kinase inhibitor, and irradiation given alone and in combination.
  • Investigations were performed using a VEGF-secreting human head and neck tumour cell line, CAL33, with a high EGFR content, injected as orthotopic xenografts into the mouth floor of nude mice.
  • Three days after tumour cell injection, bevacizumab (5 mg kg(-1), 5 days a week, i.p.
  • ), erlotinib (100 mg kg(-1), 5 days a week, orally) and irradiation (6 Gy, 3 days a week) were administered alone and in combination for 10 days.
  • As compared with the control, concomitant administration of drugs produced a marked and significant supra-additive decrease in tumour mass; the addition of irradiation almost completely abolished tumour growth.
  • The drug association markedly reduced the number of metastatic nodes and the triple combination significantly reduced the total number of pathologically positive lymph nodes as compared with controls.
  • Radiotherapy induced a strong and very significant increase in tumour angiogenesis, which was no longer observed when combined with erlotinib and bevacizumab.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cell Line, Tumor. Combined Modality Therapy. Disease Models, Animal. Drug Therapy, Combination. Erlotinib Hydrochloride. Female. Humans. Mice. Mice, Nude. Quinazolines / administration & dosage. Radiotherapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3739-47 [10999768.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21 [18058572.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1459-65 [11350918.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):293-8 [11801572.001]
  • [Cites] Laryngoscope. 2001 Oct;111(10):1834-41 [11801954.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2554-60 [11980649.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):994-1003 [12006511.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1133-40 [12008203.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4287-95 [14555497.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]
  • [Cites] Radiat Res. 1996 Jan;145(1):81-5 [8532841.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):835-42 [15701874.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):212-7 [15818163.001]
  • [Cites] Head Neck. 2005 Dec;27(12):1080-91 [16240329.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1962-71 [16373711.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):38-44 [16378905.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):45-50 [16378906.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Oncologist. 2006 Mar;11(3):274-84 [16549812.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):330-4 [16721126.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):348-64 [16713103.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1175-92 [17049015.001]
  • [Cites] Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 [17382029.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2152-5 [17538157.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2178-83 [17538162.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):65-72 [17592499.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1185-9 [17483115.001]
  • [CommentIn] Br J Cancer. 2008 Nov 4;99(9):1555; author reply 1556 [18971937.001]
  • (PMID = 18577994.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2453013
  •  go-up   go-down


7. Takayama O, Yokoyama J, Ito S: Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP. Auris Nasus Larynx; 2006 Jun;33(2):235-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP.
  • This tumor most frequently occurs in parotid gland.
  • This is the first report presenting the tumor in floor of the mouth.
  • Especially, there was not good therapy for recurrent cases.
  • We treated the patient with repeated recurrences three times and presented in bilateral parapharyngeal space to skullbase in this time.
  • In order to accomplish the both objections he received the superselective intra-arterial chemotherapy infused high-dose CDDP with radiation.
  • We confirmed tumor free in FDG-PET in 2 months after the treatment.
  • Now, we cannot detect any recurrence in 7 months after the treatment and he can eat anything and communicate anybody as before treated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / pathology. Carcinoma / therapy. Mouth Floor / pathology. Myoepithelioma / pathology. Myoepithelioma / therapy. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Injections, Intra-Arterial. Magnetic Resonance Imaging. Male. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446069.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ: (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia; 2006 Mar;8(3):163-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to chemotherapy is a common problem encountered in the treatment of head and neck squamous cell carcinoma (HNSCC).
  • Both produced tumors in a murine floor-of-mouth model that mimics human HNSCC, exhibiting growth and invasion into adjacent tissues.
  • Mice were randomized into three groups: vehicle control and two daily intraperitoneal (-)-gossypol treatment groups (5 and 15 mg/kg).
  • In the control group, tumors grew progressively, whereas in (-)-gossypol treatment groups, tumor growth was significantly suppressed.
  • Residual tumors remained growth-suppressed for 2 weeks after cessation of (-)-gossypol treatment.
  • Our results demonstrate that (-)-gossypol can inhibit tumor growth in an orthotopic model of aggressive HNSCC.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6627-31 [11426648.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):239-48 [11510695.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):638-44 [12150516.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213 [12162702.001]
  • [Cites] J Am Chem Soc. 2002 Oct 9;124(40):11838-9 [12358513.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):160-6 [12800189.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2856-65 [12855666.001]
  • [Cites] J Cell Physiol. 2003 Sep;196(3):532-40 [12891710.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6243-56 [13679863.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):8-14 [14605879.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):179-87 [15246875.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):445-51 [15254743.001]
  • [Cites] J Pathol. 2004 Aug;203(4):927-32 [15258995.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):121-39 [1327566.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]
  • [Cites] J Neurooncol. 1994;19(1):25-35 [7815102.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):72-100 [8950468.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jun;55(6):613-23; discussion 623-5 [9191644.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):398-403 [9790794.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2039-46 [9815595.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7757-63 [15570010.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):32-8 [15523684.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Life Sci. 2000 Oct 20;67(22):2663-71 [11105982.001]
  • (PMID = 16611409.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA83087; United States / NIDCD NIH HHS / DC / T32 DC05356; United States / NIDCR NIH HHS / DE / K08 DE014620; United States / NIDCR NIH HHS / DE / DE00452-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NIDCR NIH HHS / DE / K23 DE000452; United States / NIDCR NIH HHS / DE / DE014620-01A1; United States / NIDCD NIH HHS / DC / T32 DC005356; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BCL2L1 protein, human; 0 / Neoplasm Proteins; 0 / bcl-X Protein; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC1578526
  •  go-up   go-down


9. Kawashiri S, Kojima K, Kumagai S, Nakagawa K, Yamamoto E: Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice. Head Neck; 2001 Sep;23(9):764-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice.
  • METHODS: A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19, was implanted into the oral floor of nude mice, and cisplatin or peplomycin was administered to the mice 7 or 14 days after implantation.
  • The effects of each anticancer drug and different administration timings on cancer invasion and metastasis were investigated.
  • RESULTS: Tumor size and the ratio of proliferating cell nuclear antigen-positive cells was significantly reduced.
  • In the control group, the tumors showed grade 4C mode of invasion, whereas in the groups treated with anticancer drugs, grade 3 was observed in 77.3% of the mice, with an inhibitory effect on tumor invasion being observed.
  • The tumor stage progression in the metastatic lymph nodes was also inhibited.
  • CONCLUSIONS: Chemotherapy is effective not only for tumor diminution but also for inhibiting invasion and metastasis.
  • In light of these effects, administration of anticancer drugs may be clinically useful in this regard.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cell Line. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Disease Models, Animal. Drug Administration Schedule. Lymphatic Metastasis. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Peplomycin / administration & dosage. Peplomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505487.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 56H9L80NIZ / Peplomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Yamamoto G, Tanaka A, Tsuda Y, Shimada T, Nishida T, Nishikawa M, Inoda H, Takigami K, Yoshitake K: [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2533-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective].
  • We encountered a case of extensive squamous cell carcinoma ranging from the tongue to the mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective.
  • The patient was a 46-year-old male, who noticed a small mass in the mouth floor in September 2000, and visited the department of oral and maxillofacial surgery at a hospital on October 12, 2000.
  • A 27 x 15 mm tumor with erosion was noted on the mouth floor, which was diagnosed as squamous cell carcinoma by biopsy, and the patient was referred to our department for treatment on November 16, 2000.
  • MRI detected a tumor of approximately 2 cm in diameter in the area ranging from the median area of the tongue to the right ventral side of the tongue, which protruded on the mouth floor side.
  • Two courses of combination chemotherapy using nedaplatin and 5-FU were performed.
  • Adverse effects of gastralgia and stomatitis occurred, but they gradually disappeared with time.
  • The tumor with erosion in the tongue and mouth floor and induration disappeared 2 weeks after administration.
  • Postoperative MR showed no abnormal signals in T2-weighed images, suggesting that the tumor in the right mouth floor had almost disappeared.
  • External irradiation (40 Gy/20 times/28 days, 2 Gy/day, opposing bilateral portal irradiation) between March 13 and April 9, 2001, and micro-selection high dose fractionated interstitial irradiation (42 Gy/7 times/6 days, 6 Gy/1 time) April 18-23, 2001 were performed as booster therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Brachytherapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ: Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope; 2008 Feb;118(2):237-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
  • OBJECTIVES: Vesicular stomatitis virus (VSV) is a negative-strand ribonucleic acid (RNA) virus that replicates specifically in tumor cells and has oncolytic effects in a variety of malignant tumors.
  • In an orthotopic floor of mouth murine SCC model, intratumoral injections of virus combined with systemic cisplatin were tested for tumor control and animal survival.
  • RESULTS: In vitro, virus and cisplatin combination demonstrated rapid replication and enhanced tumor cell kill.
  • In vivo, combined rVSV-F with cisplatin reduced tumor burden and improved survival (P = .2 for both), while rVSV-IL12 monotherapy had better tumor control (P = .06) and survival (P = .024) than combination therapy.
  • In vivo, combination therapy enhancedrVSV-F antitumor activity, but diminished rVSV-IL12 antitumor activity.
  • Combination therapy may provide useful treatment for SCC with the development of more efficient viral vectors in combination with different chemotherapy agents or immunostimulatory agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Interleukin-12 / genetics. Oncolytic Virotherapy / methods. Vesiculovirus / genetics. Viral Fusion Proteins / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cisplatin / therapeutic use. Combined Modality Therapy. Disease Models, Animal. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Head and Neck Neoplasms / virology. Membrane Glycoproteins. Mice. Mice, Inbred C3H. Mouth Floor / pathology. Mouth Floor / virology. Polymerase Chain Reaction. RNA, Viral / genetics. Recombinant Fusion Proteins. Survival Rate. Viral Envelope Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043494.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / G protein, vesicular stomatitis virus; 0 / Membrane Glycoproteins; 0 / RNA, Viral; 0 / Recombinant Fusion Proteins; 0 / Viral Envelope Proteins; 0 / Viral Fusion Proteins; 187348-17-0 / Interleukin-12; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Gülicher D, Aumann V, Hauptmann K, Gerlach KL: [Epitheloid leiomyosarcoma of the mouth in childhood]. Klin Padiatr; 2005 Sep-Oct;217(5):291-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epitheloid leiomyosarcoma of the mouth in childhood].
  • A six-year-old girl is presented with an increasing mass involving the anterior vestibule and the floor of the mouth.
  • According to the CWS-96-study the patient underwent preoperative chemotherapy followed by complete resection of the mandibular body with the surrounding soft tissues.
  • Recurrent tumor became evident only three months later on.
  • The further treatment consisted of tumor resection, oral chemotherapy and irradiation.
  • Nevertheless tumor control could not be achieved.
  • The patient died of progressive disease 16 months after diagnosis.
  • Diagnosis is based on histologic examination and immunohistochemistry.
  • In the presented case the lack of smooth muscle actin expression made diagnosis difficult.
  • The preoperative chemotherapy could not achieve reduction of tumor size, so that extensive surgery became necessary.
  • [MeSH-major] Leiomyosarcoma. Mouth Neoplasms
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Infant. Mouth Floor / pathology. Neoplasm Recurrence, Local. Preoperative Care. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167278.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Bachmann G, Hess A, Guntinas-Lichius O, Jungehülsing M: [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth]. HNO; 2004 Jul;52(7):627-30
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth].
  • [Transliterated title] Palliative Chirurgie bei Plattenepithelkarzinom des vorderen Mundbodens.
  • A 62 year old patient presented with a bleeding, incurable squamous cell carcinoma of the anterior floor of the mouth.
  • After four palliative surgical procedures, a definitive and a palliative radiation therapy and a palliative chemotherapy, the patient remained free of tumor in the head and neck region for 2 years after the initial treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Mouth Floor / surgery. Mouth Neoplasms / surgery. Palliative Care
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Surgical Flaps


15. Buch RS, Geisbüsch R, Kunkel M: [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma]. Mund Kiefer Gesichtschir; 2002 Sep;6(5):331-5
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma].
  • BACKGROUND: The term "paraneoplastic syndrome" describes a clinically apparent disease associated with a malignant neoplasm, which is not a direct consequence of invasive tumor growth.
  • Symptoms evolved under palliative chemotherapy with gemcitabine for inoperable metachronous squamous cell carcinoma of the tonsil following a history of two simultaneous carcinomas of the alveolar crest.
  • Digital ischemia was combined with severe pain, similar to Raynaud's syndrome, which required therapeutic intervention.
  • The treatment objective is to improve perfusion and simultaneously reduce pain.
  • [MeSH-major] Alveolar Process. Carcinoma, Squamous Cell / diagnosis. Fingers / blood supply. Ischemia / etiology. Maxillary Neoplasms / diagnosis. Mouth Floor. Mouth Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Palliative Care. Paraneoplastic Syndromes / etiology. Tonsillar Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Necrosis. Raynaud Disease / therapy. Sympathectomy. Vasodilator Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12448236.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vasodilator Agents
  •  go-up   go-down


16. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Their 5-year survival in relation to age, gender, tumor site, lymph node involvement, presence of distant metastasis, staging, differentiation, and risk factors, including betel quid (BQ) chewing, cigarette smoking, and alcohol consumption, was analyzed.
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Wolf JS, Li D, Taylor RJ, O'Malley BW Jr: Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J Otorhinolaryngol Relat Spec; 2003 Sep-Oct;65(5):245-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lactoferrin, a naturally occurring glycoprotein found in breast milk, has previously been shown to have antimicrobial properties and recently has been demonstrated to inhibit malignant tumor growth, presumably through immunomodulation.
  • Using an orthotopic murine model for both squamous cell carcinoma and fibrosarcoma of the floor of the mouth, we administered lactoferrin directly into the tumors using variable dosing strategies.
  • Our results revealed growth inhibition of 50% (p=0.03)and 54% (p=0.01) as compared with controls for both human and murine tumor cells in immunodeficient and immunocompetent mice, respectively.
  • Lactoferrin proved effective in reducing malignant tumor growth in a murine model.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Fibrosarcoma / drug therapy. Head and Neck Neoplasms / drug therapy. Lactoferrin / therapeutic use
  • [MeSH-minor] Animals. Cell Line. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Immunocompetence. Injections, Intralesional. Mice. Mice, Inbred C3H. Mice, Nude. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14730178.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


18. Yang H, Liu S, Liang C, Peng W: [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan;34(1):9-11, 30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
  • OBJECTIVE: To investigate the immunological mechanism of mouse IL-2 gene therapy and the optimal lipid to DNA ratios of lipid-DNA complexed (lipoplexes) by using polycationic liposome-mediated Tumors were established in the transduction for head and neck squamous cell carcinoma (HNSCC).
  • METHODS: floor of mouth in C3H/HeJ immunocompetent mice with SCCVII cell line.
  • The supernatants of SCCVII cell and tumour tissues were collected for IL-2 expression by enzyme-linked immunosorbent assay.
  • By use of lipoplexes with L:D = 3:1, higher IL-2 expression of tumor tissues and greater activities of NK cell and CTL of murine spleen were noted in the treated group as compared with those A comparison of naked plasmid and lipid-complexed found in naked DNA and empty plasmid (EP).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy. Head and Neck Neoplasms / therapy. Interleukin-2 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Carriers. Killer Cells, Natural / immunology. Lipids. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Polyamines. T-Lymphocytes, Cytotoxic / drug effects. Transfection / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600166.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Interleukin-2; 0 / Lipids; 0 / Lipofectamine; 0 / Polyamines; 0 / polycations
  •  go-up   go-down


19. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • CONCLUSION: BSCC is a highly aggressive malignant tumor that presents in elderly patients who have a history of abuse of tobacco or alcohol, or both.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Kübler AC, Reuther T, Staff C, Haase T, Flechtenmacher C, Benner A, Scheer M, Zillmann U: [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas]. Mund Kiefer Gesichtschir; 2001 Mar;5(2):105-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas].
  • BACKGROUND: Animal tumor models are still essential for the development of new medication and therapy concepts.
  • For the field of oropharyngeal cancer only few reliable xenogeneic tumor models are available.
  • In a two-part experiment a new xenogeneic tumor model was established.
  • PART 1 OF THE STUDY: The growth rates of two different tumor cell lines were compared in the RAG-2 mouse, the SCID mouse and the Swiss nude mouse.
  • Cells from a lymph-node metastasis of an oral squamous cell carcinoma (XF-354) showed a better growth rate and clearer histology than cells from a primary squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The tumor growth rate was highest on the RAG-2 mouse, followed by the SCID mouse.
  • The Swiss nude mouse showed no tumor growth at all.
  • The combination of the XF-354 tumor cell line and the RAG-2 mouse was the most successful, with a tumor growth rate of 95%.
  • The single steps for cell cultivation and tumor implantation are described and discussed in detail.
  • Macromolecular linked photosensitizers have theoretical advantages owing to their pharmacokinetics and tumor selectivity.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Disease Models, Animal. Mesoporphyrins / pharmacology. Oropharyngeal Neoplasms / pathology. Photochemotherapy. Polyethylene Glycols / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Humans. Mice. Mice, Inbred Strains. Mice, SCID. Neoplasm Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372175.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / temoporfin-polyethylene glycol conjugate; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


21. Couch M, Saunders JK, O'Malley BW Jr, Pardoll D, Jaffee E: Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope; 2003 Mar;113(3):552-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetically engineered tumor cell vaccine in a head and neck cancer model.
  • OBJECTIVES: Using a murine model, a novel tumor vaccine for head and neck squamous cell carcinoma expressing the granulocyte-macrophage colony stimulating factor (GM-CSF) gene was evaluated for its ability to protect against tumor challenge.
  • STUDY DESIGN: Mice vaccinated in the floor of the mouth with the GM-CSF tumor cell vaccine were challenged with parental tumor cells, and subsequent tumor development was monitored.
  • Specificity of the antitumor response was demonstrated by vaccinating the mice and then challenging them with an unrelated but syngeneic radiation-induced fibrosarcoma tumor cell line, RIF.
  • Irradiated (only) tumor cells were used as a control to see whether an augmented antitumor response was attributable to possible increased immunogenicity that could theoretically be induced by the irradiation.
  • METHODS: The GM-CSF gene was transduced into tumor cells via a retroviral vector.
  • The tumor cells were irradiated to prevent replication in vivo.
  • RESULTS: Vaccination with genetically engineered tumor cells significantly protected against subsequent tumor challenge (5% level) when compared to control groups.
  • Mice were not protected when vaccinated and challenged with the unrelated tumor cell line, RIF.
  • Mice vaccinated with irradiated (only) tumor cells were not protected, either.
  • CONCLUSIONS: Vaccination with genetically engineered tumor cells offers significant protection from later tumor challenge.
  • The response is systemic and tumor specific, not due to an inflammatory response.
  • Irradiation of the tumor cells does not account for the augmented antitumor response.
  • This work supports the continued investigation of the GM-CSF tumor vaccine for the treatment of head and neck squamous cell carcinoma.
  • [MeSH-major] Cancer Vaccines / genetics. Cancer Vaccines / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Genetic Engineering / methods. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Animals. Female. Genetic Vectors / genetics. Genetic Vectors / immunology. Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Granulocyte-Macrophage Colony-Stimulating Factor / immunology. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Mice. Mice, Inbred C3H. Retroviridae / genetics. Retroviridae / immunology. Transduction, Genetic / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12616213.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


22. Lin CY, Wang HM, Kang CJ, Lee LY, Huang SF, Fan KH, Chen EY, Chen IH, Liao CT, Chang JT: Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1011-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
  • PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors.
  • METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively.
  • The median dose of RT was 72 Gy (range, 62-76 Gy).
  • Cisplatin-based chemotherapy was administered to 95% of the patients.
  • RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment.
  • The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001).
  • CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT.
  • The primary tumor extension and RT technique did not influence survival.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cause of Death. Cisplatin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiation Injuries / pathology. Salvage Therapy / mortality. Survival Analysis. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20434273.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Adappa ND, Sung CK, Choi B, Huang TG, Genden EM, Shin EJ: The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol Head Neck Surg; 2008 Sep;139(3):442-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer.
  • OBJECTIVE: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model.
  • STUDY DESIGN: In vitro and in vivo testing of immune therapy for SCC.
  • Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival.
  • In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P<0.0001) and improved median survival (38 days vs 19 days for control, P<0.0001).
  • CONCLUSION: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Interleukin-12 / administration & dosage. Mouth Neoplasms / therapy
  • [MeSH-minor] Animals. Drug Synergism. Enzyme-Linked Immunosorbent Assay. Immunotherapy / methods. Mice. Mouth Floor. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722228.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


25. O'Malley BW Jr, Li D, McQuone SJ, Ralston R: Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope; 2005 Mar;115(3):391-404
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Intralesional delivery of cytokine genes has emerged as a promising therapeutic strategy for the treatment of cancer.
  • In addition to the therapeutic effect of the delivered cytokine gene, the components of the gene delivery system also have been shown to induce beneficial immune responses.
  • On the basis of these principles, we hypothesized that a molecular therapy could be developed that would provide synergistic antitumor activity by way of intralesional expression of interleukin (IL)-2 from a recombinant plasmid combined with induction of endogenous interferon (IFN)-gamma and IL-12 cytokines by immunostimulatory DNA.
  • Our objective in these studies was to create and optimize a novel formulation of cationic lipid and DNA that generates local production of IL-2 protein within a targeted tumor environment with concomitant induction of the antitumor cytokines IFN-gamma and IL-12.
  • STUDY DESIGN: Prospective laboratory drug development plan that would produce human clinical trials.
  • MATERIALS AND METHODS: Engineered bacterial plasmids containing a cytomegalovirus promoter (CMV)-IL-2 expression cassette were specifically formulated with cationic lipids and optimized for antitumor effect in a floor of mouth murine tumor model.
  • For human clinical trials, a phase I 10 patient formulated IL-2 gene therapy study was completed.
  • Subsequently, two large scale, phase II multi-institutional and multi-international studies were initiated comparing non-viral IL-2 gene therapy to palliative methotrexate chemotherapy or in combination with cisplatin.
  • RESULTS: In the preclinical stage, maximum tumor inhibition in animal models was obtained using IL-2 plasmid formulated with 1,2-dioleyloxypropyl-3-trimethyl ammonium chloride (DOTMA):cholesterol (1:1 mol:mol) at a plasmid:lipid charge ratio of 1:0.5 (-/+).
  • Cationic lipid formulated IL-2 plasmid significantly inhibited tumor growth compared with formulated control plasmid (P < .01) or vehicle (lactose; P < .01).
  • Consistent with previously reported studies of the immunostimulatory activity of DNA of bacterial origin, treatment of tumors with control plasmid in cationic lipid formulation induced production of endogenous IFN-gamma and IL-12 but not IL-2.
  • Treatment of tumors with formulated IL-2 plasmid produced IL-2 protein levels that were 5-fold over background and increased IFN-gamma by 32-fold (P < .001) and IL-12 by 5.5-fold (P < .001) compared with control plasmid formulations.
  • The phase I human trial demonstrated dose escalation safety, which was its primary objective, and there was one anecdotal reduction in tumor size.
  • The phase II studies have been initiated and focus on either comparing the novel nonviral IL-2 gene immunotherapy formulation alone to methotrexate or comparing IL-2 gene therapy in combination with cisplatin in recurrent or unresectable patients with head and neck squamous cell carcinoma.
  • CONCLUSIONS: The preclinical data provided proof of principle for matching a delivered IL-2 transgene with an immunostimulatory nonviral formulation to enhance intralesional production of therapeutic cytokines for the maximization of antitumor response.
  • Human clinical trials have demonstrated this novel therapy to be safe in the human clinical setting.
  • Phase II trials have been initiated to assess efficacy and feasibility as a single or combination therapy for head and neck cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Head and Neck Neoplasms / therapy. Immunotherapy / methods. Interleukin-2 / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dose-Response Relationship, Drug. Double-Blind Method. Humans. Immunosuppressive Agents / therapeutic use. Interferon-gamma / metabolism. Interleukin-12 / metabolism. Methotrexate / therapeutic use. Mice. Mice, Inbred C3H. Palliative Care. Plasmids. Polymerase Chain Reaction. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transgenes

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744147.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / RNA, Messenger; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Rohde S, Turowski B, Berkefeld J, Kovács AF: [Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma--comparison with intraarterial chemoperfusion]. Rofo; 2006 Oct;178(10):979-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Klinische und histopathologische Ergebnisse nach lokaler Chemoembolisation oraler und oropharyngealer Karzinome--Vergleich mit intraarterieller Chemoperfusion.
  • The decision for iaCE or iaCP was made individually for each patient based on tumor localization and expected vascular supply.
  • Four weeks after local chemotherapy, the treatment response was evaluated according (1) to WHO criteria and (2) to histopathological TNM-grading after tumor resection.
  • RESULTS: The overall treatment response was 72.5 % after iaCE and 47 % after iaCP (p < 0.001).
  • A stable disease was found in 24 % and 48 %, respectively, and tumor progression was found in 3 % for both modalities.
  • Local side effects were significantly more frequent after iaCE than after iaCP (p < 0.001), especially in obese patients with extended carcinoma of the oral floor or the tongue base.
  • CONCLUSION: Compared to iaCP, clinical and histopathological remission rates are significantly higher after iaCE, especially in early stages of local tumor growth.
  • However, in view of the higher risk of regional complications, indication for iaCE should be considered cautiously and its application should be limited to small tumors of the oral floor and the oral tongue.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Cisplatin / administration & dosage. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Female. Germany / epidemiology. Humans. Injections, Intra-Arterial. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rofo. 2006 Dec;178(12):1266. Kovács, A [corrected to Kovács, A F]
  • (PMID = 17021977.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Reuther T, Kübler AC, Staff CJ, Flechtenmacher C, Haase T, Zillmann U: The RAG 2 mouse model for xenografted human oral squamous cell carcinoma. Contemp Top Lab Anim Sci; 2002 Mar;41(2):31-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Animal tumor models are still essential for the development of new medication and therapy concepts.
  • In the field of human oral squamous cell cancer, there are few reliable xenografted tumor models available.
  • Therefore, during a two-course experiment, we established a new xenografted tumor model of human oral squamous cell cancer.
  • The tumor growth rates of two different tumor cell lines were compared in the inbred immunodeficient CD-17-RAG 2 mouse, NMRI-SCID mouse (scid/scid), and Swiss nude mouse (nu/nu).
  • The tumor cell line from a lymphnode metastasis of an oral squamous cell carcinoma (XF 354) had a faster growth rate and a more characteristic histology than did the cell line from the primary tumor of a squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The highest tumor growth rate was observed in the RAG 2 mouse, followed by the SCID mouse.
  • The Swiss nude mouse showed no tumor growth.
  • The combination of the XF 354 tumor cell line and the RAG 2 mouse was most successful, with a tumor growth rate of 95%.
  • Our animal model is very reliable and allows manipulations for as long as 30 min under anesthesia outside of microbiologic safety cabinets, where the handling of animals is much more comfortable and less time-consuming.
  • The tumor histology was easily interpreted by using light microscopy.
  • Steps for cell cultivation and tumor implantation are described and discussed.


28. Ikeda H, Kitamura A, Uehara M, Tobita T, Ohba S, Nonaka M, Fujisawa A, Inokuchi T: [A case of squamous cell carcinoma of the oral floor showing a complete response to oral administration of UFT]. Gan To Kagaku Ryoho; 2001 Nov;28(12):1929-31
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the oral floor showing a complete response to oral administration of UFT].
  • A 73-year-old male with squamous cell carcinoma of the oral floor (T1N0M0), who had not consented to radical treatment was treated with UFT by oral administration alone.
  • After commencement of the administration, tumor remission was observed at 2 weeks and disappeared clinically at 8 weeks.
  • He remains under observation, and there is no evidence of tumor recurrence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Combinations. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11729490.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


29. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Indications for vessel occlusion are emergency situations to stop bleeding in vascular lesions (traumatic, malformation, or tumors) by reduction of pressure, preoperative reduction of blood flow to minimize the surgical risk, palliative occlusion of feeding vessels to produce tumor necrosis, or potential curative (or presurgical) occlusion of vascular malformations.
  • Examples of these interventions are: a hemangioma of the hard palate, a juvenile angiofibroma, a hemangiopericytoma, a malignant meningioma, a malignant fibrous histiocytoma, and a glomus tumor.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


30. Kummoona R: The managements of orofacial tumors of children in Iraq. J Craniofac Surg; 2009 Jan;20(1):143-50
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment modalities ranged from complete surgical excision, surgical shaving operations, and deep x-ray therapy (DXT; radiotherapy) for some benign tumors.
  • The management of malignant tumors was carried out by the use of chemotherapy, chemotherapy and DXT to radical surgery, or radical surgery with DXT.
  • Reconstruction of the mandible was carried out using a rib graft or a block of a corticocancellous bone graft from the iliac crest with reimplantation of the condyle after resection from the tumor and fixed by rigid fixation to the bone graft.
  • A temporalis muscle flap was used for the augmentation of the orbit with a frontoorbital flap after radical excision of a malignant tumor of the orbit, and a silastic implant (silicon rubber) was used for reconstruction of the orbital floor.
  • The aim of this study was to present a certain number of cases with an interesting pathologic tumor condition showing peculiar behaviors; the management of these cases was a challenge to our surgical experience.
  • [MeSH-major] Facial Neoplasms / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Transplantation. Chemotherapy, Adjuvant. Child. Child, Preschool. Diagnostic Imaging. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Iraq. Longitudinal Studies. Lymphoma / surgery. Male. Mandibular Condyle / surgery. Mandibular Neoplasms / surgery. Neoadjuvant Therapy. Prostheses and Implants. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures / methods. Skull Neoplasms / surgery. Surgical Flaps. Temporal Muscle / transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165012.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • Five-year cumulative survival rates showed significant differences between stage classifications (stage I = 91%, stage II = 73%, stage III = 63%, stage IV = 47%; p < 0.01) but not between tumor sites.
  • The 5-year cumulative survival rate was highest for oral floor cancer (80%).
  • No significant difference in regional control rates was observed between the treatment groups.
  • The 5-year survival rate for patients with cervical recurrences after primary tumor resection was 70% (n = 15).
  • In contrast, the 5-year survival rate for patients with both primary tumor resection and neck dissection was 74% (n = 14) but no significant difference was observed between these 2 groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


32. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K, Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs; 2008 Jan;19(1):85-90
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of the primary tumor were the gingiva (n=18), the tongue (n=12), the palate (n=5), the oral floor (n=4), the buccal mucosa (n=1), and the labial mucosa (n=1).
  • A median of two cycles of treatment (range, 1-5) was administered.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043133.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


33. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement